High materiality7/10
Rapport Therapeutics initiated with a Buy at UBS
Why it may matterVerify against the original reporting
UBS upgrade implies substantial upside.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS issued a Buy rating for RAPP with a target of $71 and current price of $28.33.
- UBS Buy target $71
- Price $28.33
Key facts
- 01
Target: $71
- 02
Posted price: $28.33
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.